Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
26 October 2021 | Story Nonsindiso Qwabe | Photo Nonsindiso Qwabe
From the right: Dr Ralph Clark,, with fellow researchers, Dr Stephanie Payne, Dr Sandy-Lynn Steenhuisen, Dr Onalenna Gwate and Evelin Iseli, a Swiss PhD student on RangeX at the open top chambers on the Maloti-Drakensberg mountain range.

What impact has global change had on alpine vegetation in our own mountains and those around the world, and why are certain plants in mountains around the world rapidly expanding their ranges?

This is the question on which the Afromontane Research Unit (ARU) on the Qwaqwa Campus will be shining the research lens over the next three years, through Project ‘RangeX’, a multi-institutional research consortium under the Mountain Invasive Research Network (MIREN), with ETH Zurich (Switzerland) leading the research project. The project is underway in the Witsieshoek area of the Free State component of the Maloti-Drakensberg, as part of a global consortium to better understand the ecological drivers of range-expanding plant species in mountains around the world.

South Africa’s participation in the project is led by the ARU Director, Dr Ralph Clark. Other RangeX partners are Germany, Norway, Sweden, Denmark, Australia, China, Chile, and France, with research locations in the Swiss Alps, Himalayas, Andes, Australian Alps, and Scandes.

The official launch of the research site for the Maloti-Drakensberg mountains, which took place on 20 October, marked the beginning of the South African component of globally coordinated research to understand how range-expanding species may affect current alpine environments under future climatic conditions. The launch involved a site visit to the summit of the Maloti-Drakensberg. Situated at 3 100 m above sea level in the Witsieshoek area, the research seeks to determine whether typical range-expanding species might colonise the alpine zone above 2 800 m under a simulated future warmer climate. 

The South African component of RangeX is funded by the Department of Science and Innovation (DSI) through BiodivERsA, an initiative of the European Union’s Horizon 2020, which promotes research on biodiversity and ecosystem services and offers innovative opportunities for the conservation and sustainable management of biodiversity.
Speaking at the launch of the project, Dr Clark said the alpine zone of the Maloti-Drakensberg is an ecologically severe environment, resulting in only specialised species being found above 2 800 m. “However, with climate warming, it can be expected that many lower elevation plants might start to ‘climb’ the mountain and invade its upper reaches. This will have a major impact on ecology, livelihoods, endemic alpine species, and water production.”

This is the first time that such experiments will be undertaken in the alpine context of the Maloti-Drakensberg, Dr Clark explained. The ARU is using this project to promote an ambitious and long-term alpine research programme centred on the Mont-aux-Sources area, where the Free State, KwaZulu-Natal, and Lesotho meet.  

Toto Matshediso, Deputy Director: Strategic Partnerships at DSI, said the Range X project with South African funding from the DSI was aligned with the departmental priorities for investment in global change and biodiversity research and innovation. 

“The research conducted is strengthening international cooperation in terms of research collaboration with its European Union partners as a region, as well as bilateral partners involved in the project. The project is also located in an area that has been historically disadvantaged, and the DSI is proud to be part of contributors to mountain research initiatives and direct contribution to the local community. The project also places the spotlight on the rich biodiversity data of the area, and how it could contribute to the overall government priorities regarding biodiversity.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept